PEHRG 214

Drug Profile

PEHRG 214

Alternative Names: PEHRG214

Latest Information Update: 16 Jun 2015

Price : $50

At a glance

  • Originator Virionyx
  • Class Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 23 Apr 2009 Virionyx is now called Innate Therapeutics
  • 31 Jan 2007 Phase-II clinical trials in HIV-1 infections in USA (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top